REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA.
Details of the presentations are as follows:
2022 Endocrine Society Meeting (ENDO)
| Title: | Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome |
| Format: | Oral Presentation |
| Presenter: | Dr. Eric Felner on behalf of the DESTINY PWS Investigators and Soleno Therapeutics |
| Date: | Sunday, June 12, 2022 |
| Time: | 11 AM to 12:30 PM Eastern Time |
| Title: | Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome |
| Format: | Poster |
| Presenter: | Dr. Michael Woloschak on behalf of the DESTINY PWS Investigators and Soleno Therapeutics |
| Date: | Sunday, June 12, 2022 |
| Time: | 1:00 PM ET |
The copy of the presentation materials will be available in the Investors section on the Company’s website at www.soleno.life after presentation at the meeting.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…
Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…
LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…
Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…
A Revolutionary ATCA/VME/VXI 3D-Flow Board: 512 Channels, >2,800 Programmable Operations—Scalable to >50,000 Operations on Each…
After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…